The drug is from a new class of antibiotics, the first new class in decades to be approved as a treatment for gonorrhea, ...

The U.S. Food and Drug Administration said on Thursday it has expanded the use of GSK's Blujepa as an oral treatment for ...

The FDA has proposed adding bemotrizinol, a new sunscreen ingredient, to the U.S. approval list, which could expand consumer ...

The narrow FDA labeling makes it so that only a minority of men who could benefit from treatment are considered ‘on-label’ ...

The U.S. is considering allowing bemotrizinol, a highly effective UV filter used throughout Europe and Asia, in its sunscreen ...

The Clean Label Boom Is Exploding Worldwide 1% in 2025. Honestly, those numbers tell us something powerful about where ...

A new FDA approval for a first-in-class drug has vaulted Otsuka into immunoglobulin A nephropathy (IgAN), an increasingly competitive kidney disease field targeted by multiple biopharma companies. The ...

Sibeprenlimab is approved for IgAN treatment, showing a 51.2% reduction in proteinuria in the VISIONARY trial. Administered subcutaneously every four weeks, it inhibits APRIL to reduce IgA levels.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

The MarketWatch News Department was not involved in the creation of this content. -- Enhancing Clinical Efficiency with AI Sleep Analysis: Cutting Both Cost and Time -- Joint Clinical Studies with ...

SOMNUM™ is a medical AI software solution designed to automatically analyze polysomnography (PSG) data. The system identifies sleep stages and key events—including apnea, hypopnea, and arousals—using ...

Enhancing Clinical Efficiency with AI Sleep Analysis: Cutting Both Cost and Time Joint Clinical Studies with CROs: SOMNUM™ AI Sleep Scoring Drives Higher Efficiency FDA-cleared AI solution shortens ...